Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT03538665
Previous Study | Return to List | Next Study

The DETECT Study: Discovery and Evaluation of Testing for Endometrial Cancer in Tampons

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03538665
Recruitment Status : Not yet recruiting
First Posted : May 28, 2018
Last Update Posted : August 16, 2019
Sponsor:
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Cancer Institute (NCI) )

Brief Summary:

Background:

Endometrial cancer is a common and deadly cancer for women. It is getting more common and deadly because risk factors like age and obesity are increasing. It is highly curable if it is identified early. But there may be no symptoms early or they may be missed. Also, this cancer is becoming more common and deadly for black women than white women. Researchers want to find better ways to take samples and test them for this cancer. They want to study this for a racially diverse population. One way to take samples might be from a tampon.

Objective:

To see if it is possible and acceptable to collect an endometrial sample from women by using a tampon placed in the vagina.

Eligibility:

Women at least 45 years old who are having a hysterectomy

Design:

Participants will put a tampon in their vagina at least 30 minutes before their surgery.

Participants will take a short survey.

The tampon will be collected during the surgery.

A small piece of tissue will be collected from the uterus that is removed in surgery.

Participants will give a blood sample.

Before or after surgery, participants will answer questions. These will be about their medical history and basic data such as age and race.

Researchers will follow participants medical records for up to 3 years after the study.

Researchers will study the samples and tampons. They will compare how well cancer and other markers are detected between the samples.


Condition or disease
Endometrial Cancer Endometrial Cancer Precursors

Detailed Description:

BACKGROUND:

  • Endometrial cancer is the most common and second deadliest gynecological cancer in women in the United States, with over 63,000 new cases and 11,000 deaths expected to occur in 2018. Unlike most cancers, endometrial cancer incidence and mortality are increasing, due to increases in risk factors such as obesity and population aging.
  • Racial disparities in endometrial cancer incidence and mortality have been reported, with black or African American (henceforth referred to as black ) women experiencing more rapid increases in incidence, as well as a higher burden of endometrial cancer mortality compared to other racial/ethnic groups. The underlying basis for these disparities is likely multifactorial, involving biological differences, as well as clinical factors related to access to care, delayed diagnosis, and differences in treatment and surgical management.
  • If identified early, endometrial cancer can be highly curable; however, the earliest stages may be asymptomatic, and clinical symptoms are often missed. Combining sensitive molecular testing approaches with non-invasive sampling techniques may to lead to the development of novel endometrial cancer early detection approaches with the potential to overcome disparities in access to care and time to diagnosis and treatment. We and others have recently shown that vaginal tampons offer an acceptable and feasible method for identifying molecular markers with high sensitivity and specificity for endometrial cancer. Importantly, these proof-of-principle studies have been conducted in predominantly non-Hispanic white (white) populations, and studies of molecular markers for endometrial cancer, including those involving vaginal tampons, are lacking in black women.

OBJECTIVES:

-The goal of this study is to evaluate the acceptability, feasibility, and clinical performance of vaginal tampon sampling for molecular testing of endometrial cancer early detection biomarkers in a racially diverse clinical population.

ELIGIBILITY:

-Eligible participants will include women aged greater than or equal to 45 years undergoing clinically-indicated hysterectomy for endometrial cancer, endometrial cancer precursors, or benign conditions at the University of Alabama s Division of Gynecologic Oncology.

DESIGN:

  • This is a case-control study with prospective follow-up of the electronic health record or up to 3 years. Cases will be defined as women with histologically-confirmed endometrial cancer or cancer precursors diagnosed at hysterectomy. Controls will have no histologic evidence of endometrial cancer or endometrial cancer precursors diagnosed at hysterectomy.
  • The primary endpoints of this study will be: 1) The acceptability and feasibility of vaginal tampon sampling in a racially diverse clinical population, assessed by evaluating approximately 10 items from a brief survey regarding tampon sampling and the DNA yield from the vaginal tampon, respectively and 2) The prevalence, sensitivity, and specificity of endometrial cancer driver mutations in tampon and tissue samples in cases and controls.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 900 participants
Observational Model: Case-Control
Time Perspective: Cross-Sectional
Official Title: The DETECT Study - Discovery and Evaluation of Testing for Endometrial Cancer in Tampons
Estimated Study Start Date : August 21, 2019
Estimated Primary Completion Date : December 31, 2020
Estimated Study Completion Date : December 31, 2020

Group/Cohort
Cases
Women undergoing clinically-indicated hysterectomy for endometrial cancer or precursors
Controls
Women undergoing clinically-indicated hysterectomy for benign conditions



Primary Outcome Measures :
  1. Endometrial Cancer [ Time Frame: Enrollment or at time of surgery ]
    Women with histologically confirmed diagnosis of endometrial cancer

  2. Endometrial cancer precursors [ Time Frame: Enrollment or at time of surgery ]
    Women with histologically confirmed diagnosis of precursors (e.g., atypical hyperplasia)

  3. Non-malignant uterus [ Time Frame: Enrollment or at time of surgery ]
    Women with fibroids, polyps, endometrial hyperplasia without atypia, adenomyosis, normal endometrium, or other benign conditions determined by histology and/or clinical imaging.


Secondary Outcome Measures :
  1. Acceptability of tampon sampling [ Time Frame: Prior to surgery ]
    Women will be given a 10 question survey to assess acceptability of tampon sampling

  2. Feasibility of tampon sampling [ Time Frame: During and immediately after surgery ]
    The feasibility of tampon sampling will be determined by successful tampon insertion according to protocol prior to surgery and sufficient DNA yield (e.g., 1-2ug) from the tampon sample.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   45 Years to 99 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Women undergoing clinically-indicated hysterectomy for endometrial cancer, cancer precursors, or benign uterine conditions at the University of Alabama Division of Gynecologic Oncology who are age 45 years and older.
Criteria
  • INCLUSION CRITERIA:
  • Women scheduled for hysterectomy for endometrial cancer, endometrial cancer precursors, or benign conditions at the University of Alabama Birmingham s Division of Gynecologic Oncology.
  • Age greater than or equal to 45 years. We have chosen this age range to include both peri- and postmenopausal women, who are at greatest risk for endometrial cancer. Women younger than 45 years of age will not be included because they are at very low risk for endometrial cancer and therefore are likely not the target population for early detection of endometrial cancer.
  • Ability of subject to understand and the willingness to sign a written informed consent document. Women who do not meet this criterion include potential participants who do not speak English, or have physical, mental, or emotional problems that prevent them from comprehending the nature of the study. If the potential participant has trouble reading the document, the designated study staff person may read the document to the patient, to include the basic elements of the informed consent document, per 45 CFR 46.116 (a).

EXCLUSION CRITERIA:

  • Women who are pregnant are excluded from gynecologic surgery and are therefore not eligible to participate.
  • Men are not eligible for this study as this is a disease of a female organ.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03538665


Contacts
Layout table for location contacts
Contact: Nicolas Wentzensen, M.D. (301) 435-3975 wentzenn@mail.nih.gov

Locations
Layout table for location information
United States, Alabama
University of Alabama Not yet recruiting
Birmingham, Alabama, United States, 35233
Contact: Warner Huh    205-996-4662    whuh@uabmc.edu   
Sponsors and Collaborators
National Cancer Institute (NCI)
Investigators
Layout table for investigator information
Principal Investigator: Nicolas Wentzensen, M.D. National Cancer Institute (NCI)

Publications:
Layout table for additonal information
Responsible Party: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT03538665     History of Changes
Other Study ID Numbers: 999918106
18-C-N106
First Posted: May 28, 2018    Key Record Dates
Last Update Posted: August 16, 2019
Last Verified: April 25, 2019

Keywords provided by National Institutes of Health Clinical Center (CC) ( National Cancer Institute (NCI) ):
Endometrial Cancer
Somatic Mutations
Early Detection
Tampon Sampling
Tissue Discovery

Additional relevant MeSH terms:
Layout table for MeSH terms
Endometrial Neoplasms
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Uterine Diseases
Genital Diseases, Female